公开(公告)号：EP2025749B1

公开(公告)日：2012-04-11

申请号：EP07815053.9

申请日：2007-05-30

申请人： Astellas Pharma Inc. ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： YAMAMOTO, Nobuchika ,  SAKAI, Fumihiko ,  HIGUCHI, Hirofumi ,  TORIKAI, Masaharu ,  NAKASHIMA, Toshihiro

IPC分类号： C07K16/24 ,  C12N15/09 ,  A61K39/395 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/18 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53

CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56

摘要： It is intended to provide a humanized anti-human osteopontin antibody which is superior to conventional anti-human osteopontin antibodies in terms of activities (an antigen-binding activity, a leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, hypoxic conditions or denaturants, and the like).

公开(公告)号：EP1988174B1

公开(公告)日：2011-10-12

申请号：EP07707707.1

申请日：2007-01-30

申请人： Mitsubishi Chemical Medience Corporation ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： ONO, Tomoko c/o Mitsubishi Chemical Medience Corp. ,  WATANABE, Shinichiro c/o Yokohama City University ,  FURUSAKI, Fumio c/o Mitsubishi Chemical Medience Corp. ,  IGAMI, Ko c/o Mitsubishi Chemical Medience Corp.

IPC分类号： C12Q1/37 ,  G01N33/573

CPC分类号： C12Q1/37 ,  G01N33/573 ,  G01N33/6893 ,  G01N2333/755 ,  G01N2333/96486 ,  G01N2800/32 ,  Y10T436/106664

摘要： Disclosed is a method for determination of a condition of disseminated intravascular coagulation syndrome (DIC) in a DIC patient, wherein the method comprises determining the amount and/or the enzymatic activity of a von Willebrand factor (vWF)-cleaving enzyme (ADAMTS13) (preferably also the amount of vWF). Also disclosed is a kit for determination of a condition of DIC, wherein the kit comprises an antibody capable of binding specifically to ADAMTS13 or a fragment thereof. The method enables to achieve a differential diagnosis of a thrombotic thrombocytopenic purpura (TTP) patient from a DIC patient, which has been difficult to achieve previously only based on clinical observations or only by using conventional markers.

公开(公告)号：EP2327419A1

公开(公告)日：2011-06-01

申请号：EP09773249.9

申请日：2009-05-22

申请人： Hisamitsu Pharmaceutical Co., Inc. ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： NOZAKI Chikateru ,  KAMINAKA Kazuyoshi ,  MATSUDA Junichi ,  TERAHARA Takaaki ,  KUWAHARA Tetsuji ,  TOKUMOTO Seiji

IPC分类号： A61K39/145 ,  A61K9/00 ,  A61K9/70 ,  A61K39/00 ,  A61K39/39 ,  A61K47/10 ,  A61K47/34 ,  A61K47/36 ,  A61L31/00 ,  A61M37/00 ,  A61P31/16

摘要： The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.

摘要翻译： 本发明提供了用于使用能够增强流感疫苗的免疫原性的微针装置增强的免疫原性的方法。 。根据该方法用于增强使用本微针装置的免疫原性，具有微针的微针装置由聚乳酸的，在具有A型株（H1N1）抗原组成的流感疫苗涂覆有A型株（H3N2），和类型 B株作为活性成分被带入与皮肤直接接触，以便经皮施用上述的流感疫苗。 经皮给药后，月桂醇被应用到微针系统已经直接接触皮肤的部位。

公开(公告)号：EP1602720B1

公开(公告)日：2010-11-03

申请号：EP04713206.3

申请日：2004-02-20

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： KOYANAGI, Satoshi, Chemo-sero-therap. res.inst. ,  SUGAWARA, Keishin, Chemo-sero-therap. res.inst. ,  MIYATSU, Yoshinobu, Chemo-sero-therap. res. inst. ,  MURAKAMI, Toshio, Chemo-sero-therap. research inst ,  MAEDA, Toshihiro, Chemo-sero-therapeut. res.inst. ,  MIZOKAMI, Hiroshi, Chemo-sero-therap. res.inst.

IPC分类号： C12N15/09 ,  C12P21/02 ,  C07K14/435

CPC分类号： C07K14/43531 ,  C12N15/70 ,  C12P21/02

摘要： It is intended to provide a foreign protein free from any expression inducer and a process for producing the same. Namely, a process for producing a foreign protein involving the step of proliferating a recombinant Escherichia coli, which expresses the foreign protein under the control by a promoter capable of inducing the expression due to the temperature shift, by arbitrarily culturing at a low temperature and then culturing the strain at a high temperature in the absence of an expression inducer to thereby allow the expression of the foreign protein, or the step of culturing the above Escherichia coli strain at a high temperature and thus effecting the proliferation of the cells and the expression of the foreign protein at the same time; and a foreign protein free from any expression inducer which is obtained by this process. Particular examples of such foreign proteins include main tick allergens, Actinogacillus pleuropneumoniae-origin secretory macrophage toxin and a protective antigen against Erysipelothrix rhusiopathiae-infection.

公开(公告)号：EP1676911B1

公开(公告)日：2010-04-21

申请号：EP04817298.5

申请日：2004-10-21

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： MATSUYAMA, Reiko, c/o Kikuchi Research Center ,  MAEDA, Hiroaki, c/o Kikuchi Research Center ,  SHIRAHAMA, Hitomi , c/o Kikuchi Research Center ,  IMAMURA, Takayuki , c/o Kikuchi Research Center ,  KAMACHI, Yasuharu , c/o Kikuchi Research Center

IPC分类号： C12N5/10 ,  C07K14/745 ,  C12N15/12 ,  C07K14/46 ,  C12P21/02 ,  C12N15/85 ,  C12N15/866

CPC分类号： C12P21/02 ,  C12N2510/02

公开(公告)号：EP2085093A1

公开(公告)日：2009-08-05

申请号：EP07830661.0

申请日：2007-10-26

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： HARAKAWA, Tetsuhiro ,  NAKANO, Hirotoshi ,  TORII, Yasushi ,  GOTO, Yoshitaka ,  SHINMURA, Miho ,  OKUDA, Sachio ,  KAJI, Ryuji ,  KOSAKI, Shunji

IPC分类号： A61K38/00 ,  A61K47/42 ,  A61P1/00 ,  A61P7/12 ,  A61P17/00 ,  A61P21/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/16 ,  A61P27/02 ,  A61P43/00

CPC分类号： A61K47/42 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/4893 ,  Y02A50/469

摘要： A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.

摘要翻译： 提供了一种新型的A型肉毒杆菌毒素制剂。 一种包含作为活性成分的来自肉毒杆菌的高度纯化的A型肉毒杆菌毒素作为婴儿肉毒杆菌病原体的神经肌肉阻滞剂和用于治疗肌肉过度活动的疾病的药物，其包含所述毒素作为活性成分。 特别地，与常规的已知的肉毒杆菌毒素制剂相比，本发明的药物具有快速的潜力并且扩散性较差，因此具有更宽的安全性，可用作治疗药物以减少局部，肌肉过度活动 在肌肉过度活动的疾病中。

公开(公告)号：EP1710250B1

公开(公告)日：2009-04-15

申请号：EP05703875.4

申请日：2005-01-20

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： SHIBATA, Shinichi Chemo-Sero-Therapeutic Research Inst. ,  NAKASHIMA, Kazuyuki, ChemoSeroTherapeutic Res.Inst ,  TANABE, Tetsurou, Chemo-Sero-Therapeutic Res.Inst. ,  MIYATSU, Yoshinobu, ChemoSeroTherapeutic Res.Inst. ,  MIZOKAMI, Hiroshi, ChemoSeroTherapeutic Res. Inst.

IPC分类号： C07K1/30 ,  C07K14/76 ,  C12P21/02

CPC分类号： C07K1/30 ,  C07K14/765

摘要： A method of heating a human serum albumin solution containing foreign substances from host in the presence of divalent cation, such as calcium ion, magnesium ion, nickel ion, cobalt ion, iron ion or zinc ion to thereby effect selective coagulation of the foreign substances; and a human serum albumin of high purity obtained by the method.

公开(公告)号：EP2015065A1

公开(公告)日：2009-01-14

申请号：EP06745899.2

申请日：2006-04-28

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ,  Japan as Repres. by Director Gral of National Institute of Infectious Diseases

发明人： HARAKAWA, Tetsuhiro ,  NAKANO, Hirotoshi ,  TORII, Yasushi ,  OKUDA, Sachio ,  KAJI, Ryuji ,  SAKAMOTO, Takashi ,  TAKAHASHI, Motohide ,  ISHIDA, Setsuji

IPC分类号： G01N33/15 ,  G01N33/50

CPC分类号： G01N33/5088 ,  G01N33/94

摘要： The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium , the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD 50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.

摘要翻译： 本发明涉及定量测定神经毒素的肌肉松弛活性的方法。 具体而言，基于来自梭菌细菌的神经毒素的肌肉松弛活性的程度，本发明涉及定量神经毒素的功效（潜在和/或扩散反应）的方法，其包括以下步骤:( a）将神经毒素给予非人类哺乳动物后腿之一的后腿肌肉; （b）向所述非人类哺乳动物施加电刺激; （c）通过所述神经毒素给予的所述后腿肌肉和/或未给予所述神经毒素的另一后腿的后腿肌肉的收缩来测量复合肌肉动作电位（CMAP）; （d）从通过步骤（c）中的测量获得的复合肌肉动作电位（CMAP）获取振幅数据并分析振幅降低的程度，从而量化神经毒素对肌肉放松活动的功效。 与目前用作肉毒毒素潜在单位的小鼠LD50相比，所述肉毒杆菌毒素可以以仅几个单位的水平测量，本发明神经毒素功效的定量方法允许测量的水平低至 0.01到1单位，因此是一种高灵敏度，重现性和准确性的方法。

公开(公告)号：EP2006305A2

公开(公告)日：2008-12-24

申请号：EP07737666.3

申请日：2007-03-02

申请人： Tokyo University of Science ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ,  Teijin Pharma Limited

发明人： MASUHO, Yasuhiko, c/o Tokyo University of Science ,  NAGASHIMA, Hiroaki, c/o Tokyo University of Science

IPC分类号： C07K16/46 ,  C07K16/28 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2319/30

摘要： The present inventors generated modified antibodies in which several Fc domains are linked in tandem to the C terminus of the heavy chain, and modified antibodies in which Fc domains are linked in tandem via spacers, and measured the affinity for Fc receptors, CDC activity, and ADCC activity. A previous report indicated that CDC activity is not enhanced by linking multiple Fcs. However, the modified antibodies of the present invention exhibited enhanced ADCC activity. The methods of the present invention enable provision of antibody pharmaceuticals having a marked therapeutic effect.

摘要翻译： 本发明人产生了其中几个Fc结构域与重链的C末端串联连接的修饰抗体，以及其中Fc结构域通过间隔物串联连接的修饰抗体，并测量了对Fc受体，CDC活性和 ADCC活动。 以前的报告表明，通过连接多个Fcs，CDC活动没有得到加强。 然而，本发明的修饰抗体表现出增强的ADCC活性。 本发明的方法能够提供具有显着治疗作用的抗体药物。

公开(公告)号：EP1240901B1

公开(公告)日：2008-09-10

申请号：EP00987688.9

申请日：2000-12-21

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： NAKATOMI, Yasushi ,  TOMOKIYO, Kazuhiko ,  ARAKI, Tatsuya ,  TESHIMA, Kaori ,  WATANABE, Tomoko ,  NAKAGAKI, Tomohiro

IPC分类号： A61K38/37 ,  A61K38/36 ,  A61P7/04 ,  A61K38/48

CPC分类号： A61K38/4846

摘要： Medicinal compositions for preventing and treating hemorrhagic symptoms associating abnormal blood coagulation which contain as the main active ingredient a combination of activated blood coagulation factor VII (FVIIa) with blood coagulation factor X (FX). These compositions contain no component mainly causing side effects, are highly safe and efficacious, and make it possible to easily control hemostatis. Thus, these compositions are usable in controlling the hemostatis of, for example, patients suffering from blood coagulation failure due to, for example, abnormality (including defect) in blood coagulation factors, in particular, carrying a blood coagulation factor inhibitor (antibody).